Mattson Financial Services LLC Sells 906 Shares of DexCom, Inc. $DXCM

Mattson Financial Services LLC decreased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,470 shares of the medical device company’s stock after selling 906 shares during the quarter. Mattson Financial Services LLC’s holdings in DexCom were worth $2,398,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Nvest Financial LLC bought a new stake in DexCom during the 2nd quarter valued at $225,000. Bridges Investment Management Inc. bought a new position in shares of DexCom in the second quarter worth $256,000. Patten & Patten Inc. TN increased its holdings in shares of DexCom by 6.1% in the second quarter. Patten & Patten Inc. TN now owns 82,738 shares of the medical device company’s stock worth $7,222,000 after purchasing an additional 4,780 shares during the period. Generali Asset Management SPA SGR increased its holdings in shares of DexCom by 9.4% in the second quarter. Generali Asset Management SPA SGR now owns 18,545 shares of the medical device company’s stock worth $1,619,000 after purchasing an additional 1,591 shares during the period. Finally, Curated Wealth Partners LLC bought a new position in shares of DexCom in the second quarter worth $359,000. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Up 1.4%

DXCM opened at $66.33 on Friday. The stock has a market cap of $26.01 billion, a PE ratio of 46.06, a P/E/G ratio of 1.37 and a beta of 1.47. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $93.25. The business’s fifty day simple moving average is $73.59 and its 200 day simple moving average is $77.52.

DexCom (NASDAQ:DXCM) last released its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm’s revenue was up 15.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. As a group, research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 1,466 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $80.00, for a total transaction of $117,280.00. Following the completion of the sale, the executive vice president directly owned 105,223 shares in the company, valued at $8,417,840. This represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of the company’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the sale, the director owned 51,121 shares of the company’s stock, valued at approximately $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 6,849 shares of company stock valued at $564,733. Corporate insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on DXCM shares. Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 10th. Robert W. Baird decreased their price target on shares of DexCom from $112.00 to $90.00 and set an “outperform” rating on the stock in a report on Friday, September 26th. The Goldman Sachs Group decreased their price target on shares of DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a report on Wednesday, October 1st. Mizuho upped their price target on shares of DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, July 16th. Finally, Piper Sandler upped their price target on shares of DexCom from $90.00 to $100.00 and gave the stock an “overweight” rating in a report on Thursday, July 31st. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $97.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.